Loading...
XNAS
SCLXW
Market cap41mUSD
Jun 10, Last price  
0.11USD
1D
0.00%
1Q
0.92%
IPO
-29.58%
Name

Scilex Holding Co

Chart & Performance

D1W1MN
P/E
P/S
0.01
EPS
Div Yield, %
Shrs. gr., 5y
-1.45%
Rev. gr., 5y
21.89%
Revenues
57m
+21.07%
21,033,00023,560,00031,317,00038,034,00046,743,00056,590,000
Net income
-73m
L-36.32%
-178,594,000-47,519,000-88,424,000-23,364,000-114,331,000-72,807,000
CFO
19m
P
-60,421,000-31,461,000-28,664,000-21,258,000-20,707,00019,349,000

Profile

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
IPO date
Jan 11, 2021
Employees
100
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
56,590
21.07%
46,743
22.90%
38,034
21.45%
Cost of revenue
26,330
28,427
19,851
Unusual Expense (Income)
NOPBT
30,260
18,316
18,183
NOPBT Margin
53.47%
39.18%
47.81%
Operating Taxes
(1,000)
13
4
Tax Rate
0.07%
0.02%
NOPAT
30,261
18,303
18,179
Net income
(72,807)
-36.32%
(114,331)
389.35%
(23,364)
-73.58%
Dividends
Dividend yield
Proceeds from repurchase of equity
44,638
(10,000)
96
BB yield
-79.83%
3.76%
-0.02%
Debt
Debt current
35,590
109,947
745
Long-term debt
3,760
22,271
2,075
Deferred revenue
Other long-term liabilities
24,436
4,592
4,781
Net debt
33,658
128,297
636
Cash flow
Cash from operating activities
19,349
(20,707)
(21,258)
CAPEX
(30)
(2,067)
Cash from investing activities
(2,675)
(330)
(2,067)
Cash from financing activities
(18,131)
23,582
21,171
FCF
120,415
94,252
(55,486)
Balance
Cash
3,272
3,921
2,184
Long term investments
2,420
Excess cash
2,862
1,584
282
Stockholders' equity
(556,711)
(490,229)
(375,897)
Invested Capital
425,619
451,105
418,327
ROIC
6.90%
4.21%
4.90%
ROCE
42.85%
EV
Common stock shares outstanding
131,136
130,298
134,226
Price
0.43
-79.10%
2.04
-48.87%
3.99
 
Market cap
55,916
-78.96%
265,808
-50.37%
535,562
 
EV
89,574
394,105
536,201
EBITDA
34,306
22,462
22,144
EV/EBITDA
2.61
17.55
24.21
Interest
1,963
1,068
9,604
Interest/NOPBT
6.49%
5.83%
52.82%